RRMS: Considerable differences in the cost effectiveness of treatments

Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland

ESiOR studied relapsing-remitting MS (RRMS) progression and cost of relapses based on visualization and analysis of Finnish patient-level MS register real-world (RWD) data. The real-world treatment path evidence (RWE) and costs were synthesized with e.g. DMT efficacy and safety using predictive health economic modelling.

Noteworthy differences exist between the cost effectiveness of first-line DMTs for RRMS. Furthermore, the Finnish RRMS seems to be quite aggressive and comparable to the results obtained from the British Columbia MS register.

Knowledge management was in the center of project. RWD can be turned into beneficial information, RWE. When information production is synchronized with knowledge, assessments, knowledge management and predictions are enabled.

Article Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis is freely accessible: http://www.clinicaltherapeutics.com/article/S0149-2918(17)30074-7/abstract

Additional information: Erkki Soini